Trial Profile
A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of R89674 0.25% Ophthalmic Solution in Healthy, Normal Volunteers
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Alcaftadine (Primary)
- Indications Allergic conjunctivitis
- Focus Adverse reactions
- Sponsors Vistakon Pharmaceuticals
- 20 Jun 2014 New trial record